Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02455622 · ClinicalTrials.gov registry record · Phase 4
Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age
A Phase 4 study, sponsored by Shire.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT02455622 is a Phase 4 study that has completed, run by Shire. The registered enrollment target is 21 participants.
The verdict
NCT02455622, a Phase 4 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
This long-term study will provide Elaprase treatment to children enrolled in this study and will utilize data from both enrolled patients and Hunter Outcome Survey (HOS) patient registry data to conduct the primary growth analysis to assess changes in height and weight in patients with Mucopolysaccharidosis II (Hunter syndrome) MPS II.
Interventions
- DRUG Elaprase for intravenous (IV) infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-10-28 |
| Est. Completion | 2025-07-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02455622
The ClinicalTrials.gov registry entry for NCT02455622 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Elaprase for intravenous (IV) infusion is the first listed.
NCT02455622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02455622 about?
NCT02455622 is a clinical study titled "Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age". This long-term study will provide Elaprase treatment to children enrolled in this study and will utilize data from both enrolled patients and Hunter Outcome Survey (HOS) patient registry data to conduct the primary growth analysis to assess changes in height and weight in patients with Mucopolysacch...
What is the current status of trial NCT02455622?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2015-10-28. Estimated completion is 2025-07-29.
What interventions are being tested in trial NCT02455622?
The interventions under investigation include: Elaprase for intravenous (IV) infusion (DRUG).
Who is sponsoring clinical trial NCT02455622?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.